<DOC>
	<DOCNO>NCT02348489</DOCNO>
	<brief_summary>To compare efficacy safety SGI-110 Treatment Choice adult previously untreated AML consider candidate intensive remission induction chemotherapy .</brief_summary>
	<brief_title>SGI-110 Adults With Untreated Acute Myeloid Leukemia ( AML ) , Not Considered Candidates Intensive Remission Induction</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Cytologically histologically confirm diagnosis AML ( except M3 acute promyelocytic leukemia ) accord WHO classification . Performance status ( ECOG ) 03 . Adults previously untreated AML except hydroxyurea corticosteroid . Prior hydroxyurea lenalidomide treatment myelodysplastic syndrome ( MDS ) allow . Not consider candidate intensive remission induction chemotherapy time enrollment base EITHER : 1 . ≥75 year age OR 2 . &lt; 75 year age least 1 following : . Poor performance status ( ECOG ) score 23. ii . Clinically significant heart lung comorbidities , reflect least 1 : 1 . Left ventricular ejection fraction ( LVEF ) ≤50 % . 2 . Lung diffuse capacity carbon monoxide ( DLCO ) ≤65 % expect . 3 . Forced expiratory volume 1 second ( FEV1 ) ≤65 % expect . 4 . Chronic stable angina congestive heart failure control medication . iii . Liver transaminases &gt; 3 × upper limit normal ( ULN ) . iv . Other contraindication ( ) anthracycline therapy ( must document ) . v. Other comorbidity investigator judge incompatible intensive remission induction chemotherapy , must document approve study medical monitor randomization . Creatinine clearance estimate CockroftGault ( CG ) medically acceptable formula ≥30 mL/min . Candidate intensive remission induction chemotherapy time enrollment . Candidate best supportive care , ie , candidate active therapy TC comparators . Known extramedullary central nervous system ( CNS ) AML . Second malignancy currently require active therapy except breast prostate cancer stable respond endocrine therapy . Prior treatment decitabine azacitidine . Hypersensitivity decitabine , SGI110 , SGI110 excipients . Known active human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection . Inactive hepatitis carrier status low viral hepatitis titer antiviral allow . Known significant mental illness condition active alcohol substance abuse addiction , opinion investigator , predisposes subject high risk noncompliance protocol . Refractory congestive heart failure unresponsive medical treatment ; active infection resistant antibiotic ; advance pulmonary disease require &gt; 2 liter per minute ( LPM ) oxygen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>SGI-110</keyword>
	<keyword>DNA Hypomethylating Agen</keyword>
</DOC>